Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• Amneal Pharmaceuticals has received a consensus rating of "Buy" from five analysts, with an average price target of $11.60.
• Insider trading activity includes significant sales by executives, with EVP Jason B. Daly selling 22,000 shares and EVP Nikita Shah selling 71,694 shares, representing decreases of 67.47% and 21.15% in their positions, respectively.
• Vanguard Group and Rubric Capital Management are among several institutional investors that have increased their holdings in Amneal Pharmaceuticals, indicating ongoing confidence in the company's prospects.

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) have been assigned an average recommendation of "Buy" from the five analysts that are covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $11.60.

Several equities research analysts have recently weighed in on AMRX shares. The Goldman Sachs Group started coverage on Amneal Pharmaceuticals in a research report on Friday, June 6th. They issued a "buy" rating and a $12.00 price objective for the company. Wall Street Zen downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th.

Amneal Pharmaceuticals Price Performance

AMRX traded up $0.06 during midday trading on Wednesday, hitting $9.59. 1,720,973 shares of the company's stock traded hands, compared to its average volume of 1,726,976. The company has a market cap of $3.01 billion, a PE ratio of 959.96 and a beta of 1.11. The stock's fifty day simple moving average is $8.38 and its 200-day simple moving average is $8.01. Amneal Pharmaceuticals has a one year low of $6.68 and a one year high of $9.79.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. On average, research analysts expect that Amneal Pharmaceuticals will post 0.53 EPS for the current year.

Insider Activity at Amneal Pharmaceuticals

In related news, EVP Jason B. Daly sold 22,000 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total value of $199,100.00. Following the completion of the sale, the executive vice president directly owned 10,606 shares in the company, valued at approximately $95,984.30. This trade represents a 67.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Andrew S. Boyer sold 279,244 shares of the firm's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the completion of the sale, the executive vice president owned 152,426 shares of the company's stock, valued at $1,429,755.88. This trade represents a 64.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 456,374 shares of company stock worth $4,239,042. Insiders own 17.45% of the company's stock.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC grew its position in shares of Amneal Pharmaceuticals by 5,975.0% during the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock worth $26,000 after purchasing an additional 3,107 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Amneal Pharmaceuticals during the 1st quarter worth approximately $31,000. Amalgamated Bank lifted its holdings in shares of Amneal Pharmaceuticals by 33.0% during the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock worth $46,000 after acquiring an additional 1,367 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter worth approximately $52,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Amneal Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,107 shares of the company's stock worth $98,000 after purchasing an additional 1,735 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.